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SUMMARY  
Signaling through the T cell receptor (TCR) controls adaptive immune responses. Antigen 
binding to the TCR subunits transmits signals through the plasma membrane to induce 
phosphorylation of the CD3 cytoplasmic tails by incompletely understood mechanisms. Here 
we show that cholesterol bound to the TCR transmembrane region keeps the resting TCR in 
an inactive conformation that cannot be phosphorylated by active kinases. Only TCRs that 
spontaneously detach from cholesterol can switch to the active conformation and be 
phosphorylated. Indeed, by modulating cholesterol binding genetically or enzymatically, we 
can switch the TCR between the inactive and active states. The active conformation is 
stabilized by binding to peptide-MHC ligands, which thus control TCR signaling. 
Collectively, these data are explained by a model of reciprocal allosteric regulation of TCR 
phosphorylation by cholesterol and ligand binding. Our results provide both a molecular 
mechanism and a conceptual framework for how lipid-receptor interactions regulate signal 
transduction. 
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INTRODUCTION  
Membrane lipids are thought to play a passive role in the function of transmembrane (TM) 
proteins by embedding and organizing them into lipid microdomains (Coskun and Simons, 
2011). However, in a few cases it was shown that the TM regions of proteins and certain 
lipids interact in a specific manner (Cherezov et al., 2007; Contreras et al., 2012; Coskun and 
Simons, 2011; Hanson et al., 2008). The functional implications of these interactions remain 
mostly unknown. We have previously found that the TCR specifically binds to cholesterol in 
resting cells to aid formation of TCR nanoclusters (Molnar et al., 2012). Here, we investigate 
whether this binding also regulates TCR signaling. 
The TCR consists of eight TM proteins organized in dimers; TCR, CD3, CD3, CD3. 
TCR binds to peptides presented on major histocompatibility complex (pMHC) molecules 
(Davis et al., 1998). The information on pMHC binding is transferred to the CD3 subunits, 
which are subsequently phosphorylated on immunoreceptor tyrosine-based activation motifs 
(ITAMs) by the Src-family tyrosine kinase Lck (Iwashima et al., 1994). Phospho-CD3s serve 
as docking sites for the kinase ZAP70 that becomes active at the TCR and transmits 
downstream signals. 
The mechanism of signal transduction from the extracellular domains of TCR through the 
membrane, resulting in phosphorylation of the CD3 cytoplasmic tails, is poorly understood 
(Davis and van der Merwe, 2006). Any mechanistic model needs to take into account that in 
resting T cells a large proportion of Lck is active (Nika et al., 2010), yet CD3s are not 
phosphorylated. Accordingly, several models have been proposed, including spatial 
segregation of phosphatases or sequestration of the CD3 chains (James and Vale, 2012; 
Kuhns and Davis, 2012; Shi et al., 2013; van der Merwe and Dushek, 2011; Xu et al., 2008). 
Using protease resistance, FRET and various biochemical approaches, it was shown that the 
quaternary structure of the TCR changes upon ligand binding, resulting in a reversible 
conformational change in the cytoplasmic tails of the CD3 subunits (Gil et al., 2002; Lee et 
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al., 2015; Risueno et al., 2005; Risueno et al., 2008). These studies led to the permissive 
geometry model of TCR activation (Minguet and Schamel, 2008; Minguet et al., 2007). One 
hallmark of this structural change is the regulation of the accessibility of a proline-rich 
sequence (PRS) in the CD3 cytosolic tail. In the resting, non-ligand-bound TCR state, the 
PRS cannot bind to the SH3.1 domain of the adaptor protein Nck hereafter referred to as 
inactive TCR or TCRI. By contrast, in the ligand-bound TCR state, the PRS can bind to 
SH3.1; the TCR in this state is called here the active TCR or TCRA. The switch from TCRI to 
TCRA is required for T-cell activation. This has been demonstrated by synthetic ligands that 
only evoked CD3 phosphorylation when the TCRA form was stabilized (Minguet et al., 2007) 
and by identifying point mutations in the extracellular stalk region of CD3 (such as K76T 
and C80G) that prevented the TCRI to switch to TCRA and abrogated CD3 phosphorylation 
(Blanco et al., 2014; Martinez-Martin et al., 2009). 
Here, we provide mechanistic and quantitative insight into how pMHC-binding results in the 
phosphorylation of the TCR. We present biochemical, genetic and functional evidence that 
cholesterol and pMHC/antibody ligands regulate the allosteric transitions of the TCR: in the 
resting state cholesterol binding stabilizes TCRI, ligand binding stabilizes TCRA, and only 
TCRA can be phosphorylated. 
 
 
RESULTS 
Cholesterol binds to TCR only in the resting, inactive TCR  
Within the TCR, cholesterol specifically binds to TCR (Molnar et al., 2012). We asked 
whether this binding changes upon switching the conformation from TCRI to TCRA in living 
cells. We grew Jurkat T cells in the presence of a radioactive cholesterol analogue with a UV-
inducible cross-linker group (photocholesterol) (Thiele et al., 2000). The cells were left 
unstimulated or stimulated with anti-CD3 antibodies for different times before exposure to 
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UV light (Figure 1A). Subsequently, surface TCRs were isolated to detect the radioactive 
cholesterol signals by SDS-PAGE and autoradiography (Figure 1B). Anti-CD3 Western 
blotting (WB) served as loading control. Binding of cholesterol to TCR was reduced by 
more than 50% upon antibody-binding to the TCR. Alternative experimental settings 
corroborated this finding (Figure S1A and S1B). In parallel, an SH3-pull-down (PD) assay 
using the SH3.1 domain of Nck (Gil et al., 2002) was done to quantify the amount of TCRA 
(Figure 1C and S1C). The reduction of cholesterol binding occurred concomitantly with the 
switch to TCRA and might have preceded phosphorylation of CD3 (Figure 1C). As a control, 
UV-irradiation alone had no effect on the TCRI-TCRA equilibrium (Figure S1D). Thus, in 
living cells cholesterol preferentially binds to TCRI. 
To determine whether the inability of TCRA to bind cholesterol is an intrinsic property of the 
TCR, we used a recently developed cholesterol-PD assay (Beck-Garcia et al., 2013) (Figure 
1D). Cholesterol binding was indeed reduced when TCRA accumulated due to anti-CD3 or 
anti-TCR binding and was independent of phosphorylation, since it also occurred at 0°C and 
in the presence of the Src kinase inhibitor PP2 (Figure 1E). Bub3, which also binds to the 
lipid beads (Beck-Garcia et al., 2013), served as a loading control. This reduction was also 
seen in primary human T cells (Figure S1E). In contrast to cholesterol beads, TCR binding to 
stearate or palmitate beads was independent of the TCR conformational state (Figure S1F, 
S1G, 1F and S1H). Thus, the conformational state of the TCR specifically correlated with 
cholesterol binding (Figure 1F).  
To support the finding that cholesterol preferentially binds to TCRI compared to TCRA, we 
used a CD3 with a mutation (K76T) in its extracellular stalk region, which favors the 
inactive conformation (Martinez-Martin et al., 2009) (Figure 1G). We expressed murine wild 
type (wt) and K76T CD3 in Jurkat cells (Figure S1I). Consistent with its inability to switch 
to TCRA, similar amounts of K76T TCR bound to cholesterol beads with or without antibody 
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stimulation (Figure 1H). Altogether, these data confirm that cholesterol binding to the TCR is 
conformation-selective. 
 
Cholesterol binding keeps the TCR in the non-phosphorylatable state 
To construct a TCR chain that cannot bind cholesterol, we took advantage of our finding that 
the  TCR does not bind cholesterol (Figure S2A). We surmised that cholesterol binds to the 
TCR TM region. Thus, a single-chain Fv fragment-tagged TCR chain (scTCR) (Gil et al., 
2002) mutant was constructed, in which the TM region was replaced with the TM from the 
human TCR2 chain (TMchim, Figures 2A, S2B and S2C). The TMchim TCR was expressed 
on the surface of TCR-negative Jurkat cells to the same levels as the wt TCR (Figure S2D). 
Native gel and epitope accessibility analyses suggested that the TMchim TCR assembled in 
the same stoichiometry and a similar structure as the wt TCR (Figures S2E and S2F). 
However, the resting TMchim TCR bound more weakly to cholesterol compared to the 
resting wt TCRs (Figure 2B), indicating that indeed the TCR TM region binds cholesterol. 
The residual binding of the TMchim TCR to the cholesterol-beads was not further decreased 
by antibody-stimulation and had the same level as the cholesterol-binding of the antibody-
stimulated wt TCR (Figure 2B). This suggested that the TMchim TCR does not bind to 
cholesterol. As a control, TMchim and wt TCRs bound equally well to palmitate-coupled 
beads (Figure S2G). 
Importantly, reduced cholesterol binding to the TMchim TCR promoted the active 
conformation as seen by increased binding in the SH3-PD assay in both resting and anti-
CD3-stimulated conditions (Figure 2C). The increased levels of TCRA resulted in enhanced 
basal and antibody-induced phosphorylation of CD3 (Figure 2D). This increase in CD3 
phosphorylation was physiologically relevant, since we also detected enhanced Erk 
phosphorylation and upregulation of the activation marker CD69 in the resting and in the 
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antibody-stimulated situation (Figure 2E and S2H). In conclusion, genetically ablating the 
cholesterol-binding region in the TCR increased the frequency of TCRA indicating that 
cholesterol binding regulates the TCRI-TCRA equilibrium. 
 
Cholesterol removal causes TCRs to switch to the active state 
Next, we tested whether cholesterol stabilizes the inactive state in native, wt TCRs (Figure 
3A). Reduction of cell membrane cholesterol levels by treatment with cholesterol oxidase, 
which converts cholesterol to cholest-4-en-3-one (Gimpl and Gehrig-Burger, 2007), led to a 
2-fold increase in the proportion of TCRA (Figure 3B). Moreover, lowering cholesterol levels 
enhanced basal CD3 and Erk phosphorylation (Figure 3B and 3C) as well as CD69 
upregulation (Figure S3A) in Jurkat cells. Enhanced Erk phosphorylation upon cholesterol 
reduction was also seen in primary human T cells (Figure S3B). Cholesterol oxidase treatment 
neither led to decreased cell viability (Figure S3C) nor rendered the cells unresponsive to anti-
CD3 stimuli (data not shown). Switching to TCRA and increased CD3 phosphorylation were 
also seen after we extracted cholesterol using methyl--cyclodextrin (mCD, Figure S3D). 
The induction of signaling by cholesterol removal using mCD is in line with the literature 
(Kabouridis et al., 2000; Rouquette-Jazdanian et al., 2006), and could be due to either the 
accumulation of TCRA or to other effects of cholesterol reduction, such as altered membrane 
microdomain organization (Horejsi, 2003). To test whether the stimulating effect of 
cholesterol is TCR-dependent, we used TCR-negative Jurkat cells. Cholesterol oxidase 
treatment did not lead to increased Erk phosphorylation in cells lacking a TCR (Figure 3D). 
Hence, enhanced signaling upon cholesterol extraction was TCR-dependent, and thus most 
likely caused by the accumulation of TCRA. Consistent with this conclusion, we found that in 
cells expressing the TMchim TCR, which does not bind cholesterol, cholesterol oxidation did 
not further increase the amount of TCRA or Erk phosphorylation (Figure S3E). Together, 
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these data suggest that cholesterol-binding to the TCR keeps the TCR in the TCRI state to 
prevent spontaneous signaling. 
 
Cholesterol detachment and switching to TCRA favor CD3 phosphorylation 
To confirm a gatekeeper function of cholesterol, we investigated whether cholesterol removal 
from the TCR is required for CD3 phosphorylation. We grew Jurkat cells in radioactive 
photocholesterol as before. Using UV light, we covalently linked cholesterol to the TCRs, 
hypothesizing that cholesterol-linked TCRs would not be able to spontaneously switch to the 
TCRA form, and therefore would not become phosphorylated. To detect CD3 
phosphorylation, we used the phosphatase inhibitor pervanadate that prevents removal of 
phosphate groups from CD3, hence allowing phosphorylated TCRs to accumulate; of note, 
pervanadate does not itself affect the TCR’s conformational state (Gil et al., 2002; O'Shea et 
al., 1992). First, we cross-linked radioactive cholesterol to the TCRs and then treated the cells 
with pervanadate (Figure 4A and 4B, lane 1). After lysis, phosphorylated proteins were 
purified. The autoradiography shows that cholesterol-linked TCRs were not phosphorylated 
(lane 1). Due to the low amount of radioactive cholesterol, most TCRs were bound to 
endogenous unmodified cholesterol (Figure 4A, lower panel), and those TCRs were 
phosphorylated as demonstrated by WB (Figure 4B, lane 1). This indicated that the 
cholesterol-linked TCRs were locked in a non-phosphorylatable state, and that cholesterol 
needs to dissociate from the TCR before the TCR can be phosphorylated. 
In contrast, when the cells were first treated with pervanadate to phosphorylate the TCRs and 
then exposed to UV light (Figure 4A and 4B, lane 2), radioactive and phosphorylated TCRs 
were detected. This served as a control for cross-linking of radioactive cholesterol to TCR 
and indicated that phosphorylated TCRs can switch to the TCRI state and then bind to 
cholesterol again. Indeed, phosphorylated TCRs could switch back to TCRI (Figure 4C, SH3-
PD), and bind to cholesterol-coupled beads (Figure 4C, cholesterol-PD). UV light 
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illumination alone did not alter the phosphorylation of the TCR (Figure S4A). In conclusion, 
cholesterol-bound TCRs cannot be phosphorylated in living cells, confirming that only those 
TCRs that are not bound to cholesterol are capable of switching to TCRA in order to be 
phosphorylated. 
TCRs can spontaneously switch to TCRA (de la Cruz et al., 2011; Mingueneau et al., 2008) 
and Figure 4B suggests that only TCRA can be phosphorylated (Figure 4D, upper panel). To 
test if the switch to TCRA is required for phosphorylation, we used the K76T CD3 mutant, 
whose capacity to switch to the TCRA conformation is reduced (Martinez-Martin et al., 2009) 
(Figure 4D, lower panel). The murine wt and K76T CD3-expressing Jurkat cells were treated 
with pervanadate, lysed, and the TCR was immuno-precipitated (Figure 4E). We used twice 
the amount of K76T CD3-expressing cells for the IP to compensate for the two-fold lower 
TCR expression level (Figure S1I). Indeed, similar amounts of TCRs were separated by SDS-
PAGE (Figure 4E, lowest panel), but a smaller fraction of CD3 and CD3 were 
phosphorylated in the K76T mutant (only TCRI) compared to the wt TCR (spontaneously 
switching to TCRA). Likewise, ZAP70 was more readily recruited to, and phosphorylated at, 
the wt TCR (Figure 4E and S4B). In addition, the upregulation of CD69 was impaired when 
the K76T CD3-containing TCR was stimulated with anti-CD3 compared to the wt TCR 
(Figure S4C). 
Further, to compare cells with equal surface TCR expression levels, we used flow cytometry. 
We stimulated wt and K76T CD3-expressing Jurkat cells with pervanadate and stained them 
for flow cytometry against mouse CD3, phospho-ZAP70 and phospho-Erk. Cells expressing 
equal levels of mouse CD3 were gated. Again the downstream signaling events, such as 
phosphorylation of ZAP70 and Erk, were reduced when the K76T CD3-containing TCR was 
stimulated (Figure S4D, S4E and S4F). 
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We thus conclude that CD3 phosphorylation by a ligand-independent stimulus requires that 
the TCR spontaneously adopt the active conformation. 
 
Lck can only phosphorylate TCRA 
To characterize the mechanism that allows TCRA, but not TCRI, to be phosphorylated, we 
used a synthetic system in which the wt scTCR (Gil et al., 2002) was purified using nitro-
phenol-coupled beads without altering the TCR’s conformational state. We then left the 
sample untreated (Figure 5A, TCRI) or added anti-CD3 and anti-TCR antibodies that mimic 
ligand binding and stabilize TCRA (Minguet et al., 2007). The system was supplemented with 
recombinant active Lck performing the in vitro kinase assay with the TCRs immobilized on 
the beads. In the untreated sample hardly any CD3 phosphorylation was detected (Figure 
5B), suggesting that the CD3 tails were protected in the TCRI conformation. Strikingly, 
CD3, CD3 and CD3 (Figure 5B, 5C and S5A) were more strongly phosphorylated when 
TCRA was stabilized by antibody binding. Further, the amount of TCRA (Figure 5B, lower 
panel) correlated with the amount of TCRs that were phosphorylated (Figure 5B, upper panel) 
and with the intensity of downstream signaling (Figure S5B). Likewise, recombinant Lck 
could only phosphorylate membrane-embedded TCRs when anti-CD3 antibodies (Figure 
5D) or pMHC tetramers stabilized TCRA (Figure S5C). Importantly, Lck autophosphorylation 
and LAT phosphorylation by Lck were detected independently of the TCR’s conformational 
state, demonstrating that (i) Lck was active under all conditions and (ii) the TCR state 
specifically regulated the accessibility of the TCR cytoplasmic tails for phosphorylation 
(Figure 5B and 5D). Since the recombinant Lck did not contain any fatty acid modifications, 
differential TCRA versus TCRI phosphorylation cannot be caused by differential interaction of 
Lck with the detergent micelle. Addition of cholesterol to our synthetic reconstitution system 
reduced both the spontaneous and antibody-stabilized accessibility of the CD3’s PRS 
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(TCRA) and the amount of CD3 phosphorylation (Figure 5E, F). In conclusion, an active 
kinase can phosphorylate CD3 only when the TCR is in the active state. 
 
An allostery model for the regulation of TCR activity 
Based on our understanding of the initial steps of TCR triggering, we propose a quantitative 
model that describes how cholesterol and pMHC control the conformational equilibrium 
between the TCRI and TCRA states (Figure 6A). This model provides a mechanistic basis for 
our experimental observations and is based on five premises: (1) The TCR is in 
conformational equilibrium with the equilibrium constant L = [TCRI]/[TCRA]. Thus, the TCR 
can switch spontaneously in the absence of ligand to the active state, as suggested 
experimentally (de la Cruz et al., 2011; Mingueneau et al., 2008) (Figures 2 and 3). (2) The 
conformational switch is reversible in that TCRA can revert to TCRI. This was shown earlier 
(Minguet et al., 2007). (3) Cholesterol binds to TCRI, but not to TCRA, with the affinity 
constant Kc, hence stabilizing TCRI (Figure 1). This is consistent with our finding that the 
conformational equilibrium of a mutant TCR that cannot bind cholesterol is shifted towards 
TCRA (Figure 2). (4) Only TCRA can be phosphorylated, suggested by our results using the in 
vitro kinase assay (Figure 5) and our findings that switching to TCRA through reduced 
cholesterol binding results in spontaneous signaling (Figure 2 and 3). (5) Binding of at least 
dimeric soluble pMHC stabilizes TCRA, while monovalent soluble pMHC can bind to both 
TCRA and TCRI as suggested earlier (Minguet et al., 2007). According to previous findings, 
we consider a preformed nanocluster of two TCRs (Schamel et al., 2005) and assume that 
conformational transitions in a TCR cluster are concerted (Martinez-Martin et al., 2009). The 
affinity constants for monovalent and bivalent pMHC binding are denoted by Ka and Kb, 
respectively. Assuming nanoclustering of the TCRs is not necessary; the behavior of the 
model is similar when single TCRs are clustered by being bound bi- or multivalently to 
pMHC (Figure S7). 
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To estimate the parameters of the model from the experimental data, we calculated the 
frequencies of TCRA and TCRI and their ligand-bound states in equilibrium as a function of 
Ka, Kb, Kc, L, and the concentrations of membrane cholesterol and pMHC (Supplemental 
Experimental Procedures). Quantifying the fraction of active TMchim TCR in unstimulated 
cells, which cannot bind cholesterol, we find L = 14 (Figure S6A). Thus, even in the absence 
of cholesterol the TCR has a strong propensity to be in the inactive state (7% of TMchim 
TCR are spontaneously switched to TCRA). Cholesterol binding further lowers the TCRA 
fraction 4 fold (only 2% of wt TCR are spontaneously switched to TCRA); this yields Kc x 
[cholesterol] = 1.0 (Figure S6A). Thus, cholesterol strongly augments the intrinsic propensity 
of the TCR to be inactive. With an approximate cholesterol concentration in the plasma 
membrane of 1 cholesterol molecule/nm2 (Falck et al., 2004), we obtain Kc = 10
6 m2/mol for 
the cholesterol-TCRI affinity (Figure S6B). Having fixed the parameters that define the 
resting state of the TCR, we tested the ability of the model to describe TCR activation. 
Stimulation of wt T cells with anti-CD3 experimentally increased the fraction of TCRA from 
2% to 16% (Figure S6A). Fitting the model to these numbers predicted a TCRA fraction of 
43% for the non-cholesterol binding TMchim TCR after the same anti-CD3 stimulus. We 
experimentally confirmed this prediction (40 ± 4%, Figure 6B). Taken together, these data 
show that this allosteric model quantitatively describes the active-inactive conformational 
equilibrium of the TCR and its regulation by cholesterol (all model parameters are listed in 
Figure S6B). 
An unexpected prediction of the model was that the TCR conformation controls the TCR’s 
avidity for pMHC, because only TCRA can bind pMHC bivalently (Figure 6A). To test this 
prediction, we used the OT-1 TCR, which binds to OVA-H2-Ld MHC tetramers. The mutant 
D227K-H2-Ld molecule does not bind to CD8 (Potter et al., 1989), allowing us to analyze the 
TCR-pMHC interaction only. In agreement with the model, the C80G mutant OT1 TCR, 
which cannot switch to TCRA (Martinez-Martin et al., 2009), binds less OVA-D227K-H2-L
d 
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MHC tetramers than the wt OT1 TCR (Figure 6C; points) (Blanco et al., 2014). Fitting the 
model to these data (Figure 6C, lines), we estimate Ka = 0.1 M–1 and Kb = 1755, thus 
indicating that pMHC binding by TCRA is preferred. Similar results were obtained when the 
MHC-CD8 interaction was not prevented (Figure S6C). In summary, the model predicts, and 
the experimental data confirm, strong reduction of pMHC tetramer binding by a mutant TCR 
that cannot switch to TCRA. 
Collectively, these data define the parameters for the allostery model of TCR regulation. The 
predicted dose-responses to pMHC ligand concentrations show quantitative control by 
cholesterol of TCRA levels (Figure 6D). Moreover, cholesterol, through controlling the active-
inactive state equilibrium, influences pMHC binding (Figure 6E). In conclusion, cholesterol 
emerges as a negative allosteric regulator of TCR activity that guards both the resting state of 
the TCR and modulates TCR activation by ligand. 
 
 
DISCUSSION 
In recent years, specific interactions between TM regions of proteins and membrane lipids 
have been discovered (Cherezov et al., 2007; Contreras et al., 2012; Coskun et al., 2011; 
Hanson et al., 2008) but not much is known about their functions. Here, we demonstrate that 
cholesterol binding to the TM region of TCR controls T-cell activation by regulating an 
allosteric switch in the TCR that exposes the CD3 PRS (active TCR or TCRA) and permits 
the phosphorylation of the ITAM tyrosines. This is achieved by selective cholesterol binding 
to the inactive TCR conformation (TCRI), which prevents spurious TCR activation and sets 
the activation threshold for pMHC ligands. Our findings thus show how a specific membrane 
lipid regulates receptor function. 
Our data indicate that prior to stimulation, the TCR exists in equilibrium between the TCRI 
and TCRA state. This is in line with earlier reports showing that a fraction of the TCRs are 
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spontaneously in the TCRA state in unstimulated cells (de la Cruz et al., 2011; Mingueneau et 
al., 2008). We found that on a resting, mature T cell, 98% of the TCRs are in the TCRI state, 
preventing spontaneous, ligand-independent signaling in T cells. In addition, spontaneous 
signaling is further controlled by the constant removal of CD3 phosphorylations by 
phosphatases, such as CD45 and CD148 located in the vicinity of the resting TCR (Choudhuri 
et al., 2005; Davis and van der Merwe, 2006). Our data strongly support that cholesterol 
binding stabilizes the TCRI state. Hence, a prediction of our allosteric model is that the TCRI-
TCRA equilibrium should be shifted towards the signaling competent TCRA by reducing 
cholesterol binding. Indeed, we have reduced cholesterol-binding genetically (by exchanging 
the TCR TM region) and enzymatically (by oxidizing or extracting cholesterol) and show 
that the proportion of TCRA increased, which led to increased spontaneous TCR-dependent 
signaling. Enhanced signaling in primary T cells had previously been noted in a transgenic 
mouse model expressing a similar chimeric TCR in which the TCR TM region had been 
exchanged with the one of TCR (Petersen et al., 2004); our findings now provide the 
molecular explanation for this observation.  
To prove that the capacity to be phosphorylated is dependent on the conformational state of 
the TCR, we used the phosphatase inhibitor pervanadate, which leads to accumulation of 
phosphate groups at CD3 (O'Shea et al., 1992) without manipulating the TCRI-TCRA 
equilibrium (Gil et al., 2002). Neither the K76T CD3-containing TCR, which cannot switch 
to TCRA, nor covalently cholesterol-linked TCRs, which are locked in the TCRI state, were 
efficiently phosphorylated upon pervanadate treatment. This indicated that CD3 
phosphorylation by a ligand-independent stimulus requires that the TCR spontaneously adopts 
the TCRA conformation to be phosphorylated. 
Our results raise the question of how ligand binding removes cholesterol from TCRI. Our 
quantitative allosteric model suggests that cholesterol spontaneously associates to and 
dissociates from the TCRI, with 50% of the TCRIs being cholesterol-bound. Only when a 
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TCRI is not bound to cholesterol, it can spontaneously switch to TCRA. Then the TCRA state 
can be stabilized by pMHC binding and cholesterol rebinding to TCRA is prevented. We have 
previously hypothesized that ligand binding induces the TCR to switch to the active state (Gil 
et al., 2002; Minguet et al., 2007; Risueno et al., 2005). However, our new data suggest that 
this switch occurs spontaneously and ligand binding stabilizes TCRA. Monovalent pMHC 
binding might be enough to stabilize the TCRA conformation, when pMHC is tethered to a 
surface. However, we have used soluble pMHC tetramers to quantify pMHC binding. For 
soluble ligands it was shown that minimally, a dimeric pMHC is required to stabilize TCRA 
(Minguet and Schamel, 2008) and thus, foster downstream signaling (Boniface et al., 1998; 
Cochran et al., 2000; Krogsgaard et al., 2005). This might be true in the case that the TCR 
was a preformed nanocluster (Schamel et al., 2005) or that two TCR monomers were held 
together by bivalent pMHC binding. The change in the quaternary structure of the TCR might 
include reorientation of one CD3 in respect to the second CD3 (Lee et al., 2015) without 
structural changes within one TCR heterodimer (Minguet and Schamel, 2008). 
Using quantitative data on the TCR conformational switch and our understanding of the role 
of cholesterol in regulating the TCRI-TCRA equilibrium, we developed a data-based 
mathematical model of the allosteric regulation of TCR phosphorylatability. In absence of 
cholesterol, 7% of the TCRs are in the TCRA state. However, cholesterol tightens this 
regulation and only 2% of the TCRs are in the TCRA state. This 3.5-fold increase corresponds 
to the narrow range of 2-4-fold increases in ITAM phosphorylation or ZAP70 recruitment upon 
TCR activation (Deswal et al., 2011; Kim and White, 2006; Steinberg et al., 2004). This increase 
is physiologically significant, since it results in initiation of TCR signaling as seen by phospho-
Erk and CD69 upregulation. As allosteric effects are reciprocal (Monod et al., 1965), our 
model made the remarkable prediction that the TCRI-TCRA equilibrium should also affect 
pMHC binding. While there is much experimental evidence for the reverse statement (pMHC 
binding shifts the conformational equilibrium), this was an unexpected prediction given that 
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‘retrograde’ effects of the TCR on ligand binding have not been considered. Our subsequent 
experimental data supported this prediction, showing that soluble pMHC tetramers bind with 
higher avidity to wt TCRs compared to those that are locked in the TCRI state. Thus the 
allostery model of TCR regulation proposed here implies that the avidity of a given TCR for 
antigen is not a constant but can be regulated by the conformational state of the TCR.  
Using CD3 mutants and modified ligands, it was shown that the TCRA state, as measured by 
the exposure of the CD3 PRS, was required for ligand-induced CD3 phosphorylation and T 
cell activation (Martinez-Martin et al., 2009; Minguet et al., 2007). Since only the exposed 
PRS binds to Nck, it was suggested that Nck plays a role in CD3 phosphorylation (Blanco et 
al., 2014; Borroto et al., 2013; Mingueneau et al., 2008). However, our data suggest an 
alternative mechanism. Only in the TCRA state, and not in the TCRI state, the ITAM tyrosines 
are phosphorylatable. This provides a molecular mechanism for how non-triggered TCRs are 
protected from phosphorylation in the presence of active Lck (Nika et al., 2010). Hence, our 
model explains how cholesterol aids to keep the TCR inactive and how ligand-binding 
induces TCR phosphorylation by stabilizing TCRA. The molecular events described in our 
novel model most likely precede the phosphorylation- or Ca2+ influx-induced dissociation of 
the CD3 and CD3 cytoplasmic tails from the plasma membrane (Aivazian and Stern, 2000; 
Shi et al., 2013; Xu et al., 2008).. In fact these mechanisms might serve to facilitate further 
phosphorylation and hence, sustain T-cell activation signals. 
It has been reported that extraction of cholesterol using methyl--cyclodextrin (mCD) 
followed by antibody stimulation leads to reduced TCR signaling, most likely due to 
disruption of lipid rafts (Montixi et al., 1998; Xavier et al., 1998). In contrast, when mCD is 
used as a stimulus, i.e. when signaling is analyzed immediately after the mCD treatment, the 
TCR is triggered (Kabouridis et al., 2000; Rouquette-Jazdanian et al., 2006). We now provide 
a molecular mechanism for the stimulatory effect of mCD, by demonstrating that lowering 
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cholesterol levels leads to an increase in TCRA that can be phosphorylated. Our data also 
suggest that cholesterol exerts its effect on TCR signaling directly at the TCR, since (i) 
cholesterol oxidation did not induce signaling in a TCR-deficient T cell line, (ii) the TMchim 
TCR showed enhanced signaling and (iii) binding of cholesterol to the TCR prevented CD3 
phosphorylation. 
Our new findings can be integrated with existing models of TCR activation and several 
molecular events might occur simultaneously. The change in the conformational state of the 
TCR most likely includes the TM regions, such as the one of TCR (this study) and CD3 
(Lee et al., 2015), the cytoplasmic tails of CD3, CD3, CD3 and CD3 (Gil et al., 2002; 
Risueno et al., 2008; Xu et al., 2008)(this study) and the extracellular arrangement of at least 
two TCRs (this study). At the same time ligand binding could segregate phosphatases from 
the TCR to allow phosphorylation to accumulate (Choudhuri et al., 2005; Davis and van der 
Merwe, 2006). Aggregation of TCRs could increase the local concentration of Lck and reduce 
the lateral mobility of the receptor, co-clustering of the TCR with the co-receptors CD4 and 
CD8 might stabilize the pMHC TCR interaction and recruit additional Lck molecules. 
Further, mechanical forces elicited by pMHC binding (Kim et al., 2009) as well as other lipids 
might play a role. 
Cholesterol is also involved in the formation of TCR nanoclusters (Molnar et al., 2012; 
Schamel et al., 2005), and thus has two apparently opposing effects in respect to pMHC 
binding. By inducing TCR nanoclustering, cholesterol enhances the avidity towards pMHC 
tetramers. In contrast, by stabilizing the TCRI state, cholesterol decreases the avidity. Using 
our mathematical model, we simulated reduction of the cholesterol concentration and found 
that the impact of changing the TCRI-TCRA equilibrium on pMHC tetramer binding is rather 
small (maximal 3 fold). Furthermore, experimental cholesterol-extraction reduced pMHC 
tetramer-binding to T cells (Fahmy et al., 2001; Molnar et al., 2012). Thus, the nanoclustering 
function of cholesterol predominates in regulating the avidity towards pMHC tetramers. We 
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suggest that cholesterol has a dual role at the TCR, enhancing the sensitivity to agonistic 
ligands but still restraining spontaneous signaling, which might be especially important in the 
case of antigen-experienced T cells (Kumar et al., 2011). Since different T cell developmental 
and differentiation stages contain different levels of cholesterol (Brumeanu et al., 2007; 
Kaech et al., 2002; Tani-ichi et al., 2005), it could be that changes in the plasma membrane 
cholesterol level contribute to regulate TCR activity and thereby, T cell sensitivity in vivo. 
In conclusion, we show here that the specific interaction of the TCR TM region with 
cholesterol regulates TCR triggering and T cell activation. In contrast to the long-standing 
assumption that the plasma membrane is an inert solvent that does not impact on the 
conformation or activity of membrane proteins, we clearly demonstrate that cholesterol 
binding to the TCR regulates CD3 phosphorylability. Lipids therefore not only play a role in 
the activation of T cells but also in guarding their resting state. Our work provides a novel 
paradigm for how the activity of TM proteins can be regulated. 
 
 
EXPERIMENTAL PROCEDURES 
 
Photocholesterol labelling 
[3-3H]6-azi-5-cholestan-3-ol (radioactive UV-light cross-linkable cholesterol, 
photocholesterol) was provided by Dr. Thiele. Jurkat cells were incubated for 16 hours in 
lipid-free medium containing a radioactive cross-linkable cholesterol-mCD complex (5 
Ci/ml) and UV-irradiated for 30 seconds, before or after the indicated times of adding the 
stimulus (anti-CD3, UCHT1, or anti-TCR, Jovi1). After cell lysis, IPs were performed as 
indicated. Samples were separated by running two SDS-PAGE gels in parallel. One gel was 
dried and exposed to an X-ray film (autoradiography), and the corresponding second gel 
subjected to WB. Alternatively, membrane patches were prepared as outlined above, the 
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TCRA state-stabilizing antibody was given at 37°C and after UV irradiation, the membranes 
were lysed and analysed as above.  
 
Synthesis of beads coupled to stearate, palmitate and cholesterol 
The synthesis of the stearate-, palmitate- and cholesterol-coupled sepharose beads was as 
described (Beck-Garcia et al., 2013). In brief, the carboxygroups of stearate, palmitate or 
cholesteryl hemisuccinate were activated by N,Ndiisopropyl-ethylamine and O-(benzotriazol-
1-yl)-tetramethyluronium tetrafluoroborate and coupled to -aminohexyl agarose beads. The 
completeness of the reaction was tested by a Kaisertest. 
 
SH3-PD assay, lipid-PD assay, IP and immunoblotting 
Lysates were subjected to the SH3-PD assay using SH3.1(Nck)-GST bound glutathione-
coupled beads as described (Gil et al., 2002). The cholesterol-, stearate- and palmitate-PD 
assays were also done as described (Beck-Garcia et al., 2013); after the PD the beads were 
washed 3 times with lysis buffer containing 0.05-0.5% Brij96V. In these PD assays, the 
detergent molecules and possibly some of the endogenous lipids, are bound to the TM regions 
of the TCR. Thus, those molecules might have mediated or modified the interaction of the 
lipid-coupled beads with the TCR. However, radioactive cholesterol was directly crosslinked 
to the TCR chain, showing that cholesterol directly binds to the TCR in living cells. 
Anti-TCR IPs were performed with 2 g of anti-CD3 or anti-TCR antibodies overnight at 
4°C. Anti-phosphotyrosine IPs were performed with anti-phospho-tyrosine antibody (PT-66)-
coupled beads (Sigma). Samples were subjected to SDS-PAGE separation and transferred to 
PVDF membranes. Western blotting (WB) was performed by conventional methods. 
Quantifications of the band intensities were done with the Image Studio Ver 2.0 (LI-COR), 
with the ImageJ program or the ImageQuantTL software (GE Healthcare) after fluorescence 
or chemoluminescence detection. 
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Reconstitution of CD3 phosphorylation 
2 x 108 31-13.scTCR cells were lysed in lysis-buffer containing 1% digitonin or 
0.5% Brij96V. The lysate was divided into equal parts. One part of the lysate was left 
untreated, and 5 g of anti-CD3 antibody (OKT3 or UCHT1) or anti-TCR antibody (Jovi1) 
was added to the other parts. Antibodies were allowed to bind to the scTCR on ice for 30-90 
min. 7 mM cholesterol in EtOH or EtOH alone was then added when indicated. Afterwards, 
the scTCRs (and bound antibodies) were purified with nitro-phenol-coupled-sepharose beads. 
After washing, 50 ng active, recombinant GST-Lck and 1 M ATP were added in kinase-
buffer (40 mM HEPES, 10 mM MgCl2, 2 mM MnCl2) and incubated for the indicated times at 
37°C. Presence of the TCRA state or antibody binding to the TCR was controlled by SH3-PD 
or binding to protein G-sepharose, respectively. 
 
Upregulation of CD69 
To quantify the degree of T-cell activation, we stimulated the cells for 6-7 hours with the 
indicated stimuli. After harvesting, cells were stained with an APC-coupled anti-CD69 
antibody (Invitrogen), washed and analyzed with a Calibur (BD Biosciences) or a Gallios 
(Beckman Coulter) flow cytometer. Fluorescence intensities were analyzed with FlowJo 8.2 
software.  
 
Statistical analysis  
Error bars depict standard error of the mean (SEM). Statistical significance and linear 
regression were determined with GraphPad Prism as indicated: * p < 0.05, ** p < 0.01, *** p 
< 0.001. The significances were calculated by Student´s t-test as indicated (see below). 
 
Supplemental Information 
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FIGURE LEGENDS 
 
Figure 1. Active TCRs cannot bind to cholesterol 
(A) Cholesterol only binds to the inactive TCR (TCRI, upper panel). Active TCRs (TCRA) 
accumulate when bound to anti-CD3, anti-TCR or pMHC and do not bind to cholesterol 
(lower panel). Radioactive photocholesterol can be covalently cross-linked to TCR upon UV 
light exposure. 
(B) Jurkat cells were grown with photocholesterol, and were either UV-irradiated and then 
stimulated with anti-CD3 (OKT3) for the indicated times at 37°C (-); or stimulated first and 
then UV-irradiated (+). Protein G-beads were added to the lysate to capture antibody-bound 
TCRs. Purified proteins were separated by SDS-PAGE and autoradiography and WB were 
performed. For quantification, the intensity of the radioactive band corresponding to 
cholesterol-bound TCR was divided by the intensity of the anti-CD3 WB, the different time 
points were pooled, n=6. p<0.01 by two-sided one-sample t-test. 
(C) Jurkat cells were stimulated as in (B) and the SH3-PD assay was performed. SH3-bound 
proteins and the lysates were analyzed by WB. SH3-GST serves as a bead loading control. 
The intensity of CD3 in the SH3-PD was normalized to the SH3-GST signal in the PD 
pooled from different time points, n=4, p<0.05 by two-sided one-sample t-test. 
(D) In the cholesterol-PD assay, only TCRI binds to cholesterol-coupled beads. 
(E) Jurkat cells were left untreated or stimulated with anti-TCR (Jovi1) or anti-CD3 at 37°C 
for 5 min or at 0°C in the presence of PP2 for 2 hours. Lysates and the proteins purified upon 
the cholesterol- and SH3-PD were visualized by WB, n=5. 
(F) WB signals of cholesterol- and stearate-PD assays were quantified, normalized, and the 
relative amounts of TCRs bound to the lipid (lipid-PD assay, CD3/Bub3) are plotted versus 
the normalized, relative amount of TCRA (SH3-PD assay, /SH3-GST). The quantification of 
4-8 experiments assaying TCR binding to lipid and of 3-6 experiments assaying the TCR 
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conformational state were pooled. p-value indicates whether the slope calculated through 
linear regression is significantly non-zero. 
(G) In contrast to the wt TCR, the K76T TCR does not switch to TCRA. 
(H) Jurkat cells expressing wt or K76T murine CD3 were stimulated with anti-murine CD3 
(145-2C11) for 5 min and the cholesterol-PD assay was performed. Quantification (n=5) is 
shown on the right, *p<0.05 by two-sided one-sample t-test. 
 
Figure 2. A mutant TCR with reduced cholesterol binding switches to the TCRA state  
(A) wt TCRs bind cholesterol via the TCR TM region. The TMchim TCR is composed of 
the ectodomains of TCR and the TM region of TCR2 (orange) and does not bind 
cholesterol. 
(B) wt scTCR- and TMchim scTCR-expressing cells were left untreated or stimulated with 
anti-CD3 (OKT3) for 5 min and the cholesterol-PD assay was performed as in Figure 1E 
(n=4). 
(C) Cells treated as in (B) were subjected to the SH3-PD assay as Figure 1E (n=3). 
(D) Cells treated as in (B) were lysed, an IP using OKT3 and WB were done as indicated. The 
ratios of the band intensities of phospho-/ (n=4-9) and phospho-/ (n=4-11) obtained from 
the TMchim TCR were normalized to the corresponding ratio obtained from the wt TCR, 
***p<0.001 by two-sided one-sample t-test. 
(E) Cells were treated as in (B) and analyzed for phospho-Erk and Erk by WB (n=5). 
 
Figure 3. Cholesterol prevents spontaneous signaling 
(A) Cholesterol removal from the TCR results in switching to the TCRA state and thereby to 
spontaneous signaling. 
(B) Jurkat cells were left untreated or incubated with cholesterol oxidase for 1 hour. After 
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lysis, an SH3-PD and anti-CD3 IP were performed. Purified proteins and the lysate were 
analyzed by WB. The band intensities (n=4) were quantified and plotted normalized to the 
non-treated cells (TCRA:  (SH3-PD)/SH3-GST /  (IP); phospho-Erk: phoshpo-Erk 
(lysate) /  (lysate)), *p<0.05, ** p<0.01 by two-sided one-sample t-test. 
(C) Jurkat cells were treated with cholesterol oxidase for 5 min at 37°C or left untreated and 
lysed. TCRs were purified by an anti-CD3 IP. WB was done as indicated. The band 
intensities were quantified and plotted as phospho-CD3 / CD3 (n=3), *p<0.05 by two-sided 
one-sample t-test. 
(D) TCR-negative Jurkat cells were treated as in (B) and the amount of phospho-Erk was 
quantified as in (B) (n=3). 
 
Figure 4. In living cells cholesterol-bound TCRs cannot be phosphorylated 
(A, B) Jurkat cells grown in radioactive photo-cholesterol (red star) were either first exposed 
to UV light and then stimulated with pervanadate (lane 1), or first stimulated with 
pervanadate and then exposed to UV light (lane 2). The cells also contain endogenous 
cholesterol that cannot be cross-linked to the TCR (depicted without the star). After cell lysis, 
only phosphorylated TCRs were purified using an anti-phospho-tyrosine beads. Proteins were 
separated by reducing SDS-PAGE and an autoradiography and WB was done (n=2). 
(C) Jurkat cells were left untreated or stimulated with pervanadate. The lysate was split into 3 
parts; the cholesterol- and SH3-PD assays were performed (top and middle panels), and the 
lysates were analysed (lower panels) (n=3). 
(D) TCRs are in equilibrium between the inactive (TCRI, blue), active (TCRA, red) and 
phosphorylated states. In resting cells, the TCRI state and phosphatase activity dominate, so 
that most TCRs are non-phosphorylated. The K76T TCR cannot switch to TCRA. 
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(E) Jurkat cells expressing wt or K76T murine CD3 were stimulated with pervanadate. Cell 
numbers were adjusted to the same amount of murine CD3 molecule numbers on the cell 
surface. After lysis, TCRs were isolated with anti-mouse CD3 antibodies. WB was done as 
indicated (n=3). 
 
Figure 5. Only TCRA is accessible to be phosphorylated by kinases 
(A) TCRI is not amenable to phosphorylation by active Lck. Ligand stabilizes TCRA, so that it 
can be phosphorylated by Lck. 
(B) Buffer alone (-), anti-CD3 or anti-TCR were added to scTCRs bound to nitro-phenol-
coupled beads. After further addition of recombinant active Lck and ATP, the kinase reaction 
was incubated at 37°C for 30 minutes. The WB was developed with anti-phospho-tyrosine 
(4G10, visualizing phospho-Lck), pan anti-phospho-CD3, anti-phospho-Y1, and anti-CD3. 
The SH3-PD assay was performed in parallel.  
(C) Quantification of the amounts of phospho-CD3 (n=5) and phospho-Y1 (n=7) relative 
to CD3 and normalized to unstimulated condition is shown, ** p < 0.01, *** p < 0.001 by 
two-sided one-sample t-test. 
(D) Membrane patches of scTCR cells were treated with anti-CD3 antibodies or left 
untreated. Samples were treated as in B (n=2).  
(E) Cholesterol was added to purified scTCRs (chol) or not (-). Then, anti-CD3 antibodies 
were given and the SH3-PD was performed (n=3). In parallel, protein G-coupled sepharose 
was added and purified TCRs analyzed by WB. 
(F) A reconstituted CD3 phosphorylation reaction was done as in (B), in the presence or 
absence of cholesterol (n=3). 
 
Figure 6. A lipid-regulated allosteric model for TCR triggering 
 30 
(A) On resting T cells, most TCRs adopt the inactive conformation, of those 50% are bound 
to cholesterol (TCRI,c) and 50% are not (TCRI,-). Only TCRI,- spontaneously switches to 
TCRA. Monovalent pMHC binds equally well to both TCRI and TCRA. The allosteric switch 
to TCRA allows pMHC dimers with a permissive geometry to bind bivalently, stabilizing 
TCRA. Only TCRA can be phosphorylated. 
(B) After anti-CD3 stimulation the percentage of TCRA was measured experimentally by the 
SH3-PD assay for the wt and the TMchim TCR (black dots, n=4) or predicted from the model 
(red dots). 
(C) Lymph node cells of OT-1 TCR transgenic mice expressing wt (red) or C80G CD3 (a 
mutant that cannot switch to TCRA, green) were stained on ice for 30 min with increasing 
concentrations of PE-labeled OVA-D227K-H2-Kb tetramers and with an APC-labeled anti-
CD3 antibody (17A2) and measured by flow cytometry. We gated on cells with similar TCR-
expression levels. The MFI values of the bound tetramer were normalized to the amount of 
surface TCR (n=3), * p < 0.05, *** p < 0.001 by unpaired t-test. The best fit of the model to 
the experimental data is shown by solid lines, the 95% confidence intervals of the fit as 
colored areas. 
(D) Dose-response curves of the fraction of TCRA as a function of the concentration of 
D227K-pMHC tetramer (left) and as a function of cholesterol concentration (right) were 
calculated by the model. Parameters as in Figure S6B. 
(E) Dose-response curves of the fraction of bound D22K-pMHC tetramer as a function of the 
cholesterol concentration were calculated by the model. Parameters are as in Figure S6B. 
Figure 1
D E 37°C 0°C + PP2
ε
ζ
Bub3
ζ
: stim.
ζ
SH3-
GST
ch
ol
es
te
ro
l-P
D
lys
at
e
SH
3-
PD
α
-
CD
3ε
- α
-
TC
Rβ
α
-
CD
3ε
- α
-
TC
Rβ
F
0.4 0.9 1.4 1.9 2.4 2.9
0.5
1.0
TC
R 
bi
nd
in
g 
to
 lip
id
stearate
p =  n.s.
b = -0.0
cholesterol
p =
b = -0.7chol
binding
bead
ligand
no binding
bead
unstim.
α-TCRβ, 37°C
α-CD3ε, 37°C
α-TCRβ, 0°C
α-CD3ε, 0°C
A B C
TCRβ
ζ
ε
autoradiography
26
21
54
0.5 2 20
a
n
ti-
CD
3 
IP
 min
Western blot
+-- +-- +-- : stim.
1 2 3 4 5 6
p -ζ
19
34SH
3-
PD
1 2 3 4 5 6
+
0.5 2 20
-- +-- +-- : stim.
 min
19ly
sa
te p -ζ
SH3-GST
ζ
ζ
1 2 3 4 5 6
17
26
43
17
34
26
17
- -
***
 CD3
 CD3
ligand
radioact.
chol.
 UV X-link
αβ
αβ
 UV
0
2
4
CD3CC
*
+-0.0
0.5
1.0
chol. binding
**
+-
H
34
Bub343
ζ
-
- α
-
CD
3ε
wt
-
- α
-
CD
3ε
K76T
1 2 3 4
0
1
2
wt
*
+-
K76T
+-
n.s.
G
wt
K76T
 αβ
 αβ
TCR I
TCRA
TCR I
TCRA
relative amount TCRA
Figure 1
Figure 2
A B
ζ
- :stim
w
t
TM
ch
im
cholesterol-PD
lysate
1 2 3 4
w
t
TM
ch
im
chol.
α β
 CD3
α β TMchim
 CD3
no chol.
binding
43
34
Bub3
ζ34
α-CD3ε C
26
34
34
ζ
SH3-
GST
ζ
CD3 IP
1 2 3 4
SH3-PD
- α-CD3ε
w
t
TM
ch
im
w
t
TM
ch
im
:stim
43
43
E
1 2 3 4
p -Erk
Erk
- α-CD3ε
w
t
TM
ch
im
w
t
TM
ch
im
:stim
D
ε
w
t
TM
ch
im
w
t
TM
ch
im
1 2 3
α
-
CD
3 
IP
p -ε
p -ζ
-
4
α-CD3ε :stim
- α-CD3ε
n.s.
***
0
2
4
0
1
2 n.s. ***
- α-CD3ε
p 
-ζ
p 
-ε
fold increase  TMchim / wt
Figure 2
Figure 3
A B
C TCR-negative cells
- chol.
ox.
0
2
*
1
3
- chol.
ox.
0
1.0
0.5
1.5 **
p -Erk
D
- chol.ox.
n.s.
0
1.0
0.5
p -Erk
inactive
αβ
chol
active
Erk
p
1 2
SH3-
GST
lysate
SH3-PD
ζ
ζ
α-CD3 IP ζ
cho
l.ox
.
--
17
34
17
43
34
p -Erk
43 Erk2
ε
p -ζ
ζ
α
-
CD
3 
IP
ch
ol
.o
x.
-
1 2
co
n
to
l I
P
3
p 
-ζ 
/ ε **
0
1
- chol.ox. 1 2
cho
l.ox
.
43
34 ζ
--
p -Erk
43 Erk2
p
relative
amount
TCRA
Figure 3
Figure 4
BA C
54
autoradiography
UV
   
   
pe
rv
an
.
pe
rv
an
.  
   
 U
V
28
50
28
a
n
ti-
ph
os
ph
o-
ty
ro
sin
e 
IP
1 2
ε
ζ
Bub3
: stim.
WB:
ch
ol
es
te
ro
l P
D
-- pe
rv
an
.
1     2
17
26
43
radioactive photocholesterol
lane 1
radioact. chol.
UV X-link
lane 2
 UV
 X-link
endogenous cholesterol
lanes 1 + 2
D
E 0
w
t
K7
6T
w
t
K7
6T
w
t
K7
6T
50 100 : pervan.
        µM
1 2 3 4 5 6
72 ZAP70
72 p -ZAP70
p -ε
p -ζ
26
34
43
ζ34
TCRβ
WB:
ε
 p -
tyrosine
ζ
SH3-
GSTS
H3
-P
D
17
34
ζlys
at
e
17
26 p -ζ
Lck
K76T mutant
 αβ
 αβ
p
P ase
p p
p p
Figure 4
Figure 5
phospho-εY1
C D
BA
E
ε
SH3-
GST
ε
+
- chol.
-- +--
1 2 3 4
: stim.
26
34
26
SH
3-
PD
pr
ot
G
 IP
F
p -Lck
p -ζ
p -εY1
ζ17
1 2 3 4
26
+
- chol.
-- +- : stim.
26
95
+
 L
ck
 +
 A
TP
CD3 Lck
αβ
ligand
Lck
0
2
4
6
p -ζ / ε
*** **
stim.:
α
-
CD
3ε
α
-
TC
Rβ-
p -εY1 / ε
0
1
2
3
α
-
CD
3ε
α
-
TC
Rβ-
* *
SH3-PD
17 ζ
α
-
CD
3ε
-
p -εY126
p -LAT34
p -Lck85
1 2
17
: stim.
α
-
CD
3ε
- α
-
TC
Rβ
85
+
 L
ck
 +
 A
TP
SH3-PD
lysate
1 2 3
ε
ζ
26
ε
17
p -Lck
p -ζ
p -εY1
αβ
p p
TCR I
TCRA
Figure 5
Figure 6
A
CD3
αβ
αβ
L
pMHC
dimer
Ka Ka
αβ
chol. allosteric
switch
L
Kc
TCR I,c
inactive conformation
active
conformation
phosphorylation
TCR I,-
Kc
αβ
B
%
 a
ct
ive
 T
CR
0
10
20
30
40
model exp. model exp.
50
wt TMchim
n.s.
u
po
n 
α
-
CD
3ε
 
st
im
.αβ αβ
Ka
Kb
TCRA
        nM D227K tetramer
n
o
rm
a
lis
ed
 te
tra
m
er
 b
in
di
ng wt
C80G
D
        nM D227K tetramer             molecules/nm2 cholesterol             molecules/nm2 cholesterol
 
 
 
 
 
 
 
 
 
fra
ct
io
n 
of
 T
CR
A,
 
%
 
 
 
 
 
 
fra
ct
io
n 
of
 
 
 
 
 
 
bo
un
d 
te
tra
m
er
,
 
%
E
αβ αβ
αβ αβ
αβ αβ
C
Figure 6
	  	   1	  
SUPPLEMENTAL INFORMATION 
 
 
 
 
 
Figure S1.  Active TCRs do not bind to cholesterol, Related to Figure 1 
(A) Jurkat cells were grown with radioactive photocholesterol, and were either exposed to UV light and then treated with anti-CD3ε 
(UCHT1) or anti-TCRβ (Jovi1) antibodies for 20 min at 37°C (-); or stimulated first and then exposed to UV light (α-CD3ε, α-TCRβ). After 
cell lysis, additional anti-CD3ε or anti-TCRβ antibodies were added, to immunoprecipitate all TCRs using protein G-sepharose beads (lanes, 
1, 2, 5, 6). Alternatively, protein G-sepharose beads alone were added, in order to capture the antibody-bound cell surface TCRs (lanes 3, 4). 
Purified proteins were separated and analysed as is Figure 1B. 
(B) Jurkat cells were grown with radioactive photocholesterol and membranes patches were prepared as described in Supplemental 
Experimental Procedure. Stimulation and analysis were done as in A. 
(C) The SH3-PD is graphically depicted. In the TCRI state (blue), the CD3ε proline rich sequence is not available for binding to the GST-
coupled Nck SH3.1 domain bound to glutathione beads. In contrast, antibody- or pMHC-stimulated TCRs are in the active conformation 
(TCRA, red), allowing the proline-rich sequence to bind to the SH3-bound beads. 
(D) Jurkat cells grown without photocholesterol were left unstimulated or treated with anti-CD3ε antibodies for 2 hours at 4°C. 
Subsequently, cells were UV irradiated or not. The SH3-PD assay and a protein G-coupled sepharose IP were performed. Purified proteins 
and the lysate were analysed. The data show that irradiation with UV light per se did not affect the conformational state of the TCR. 
(E) Human peripheral blood mononuclear cells (PBMCs) from a healthy donor were left unstimulated (-) or treated for 5 min at 37°C with 
anti-CD3ε (UCHT1). The cholesterol- and SH3-PD assays were performed as in Figure 1E. 
(F) The TCR and the transferrin receptor (TfR) were purified from M.mζ-SBP and M.hTfR-SBP cells through the streptavidin-binding 
peptide (SBP) with streptavidin-coupled beads and then eluted with 4 mM biotin. The BCR was purified from J558Lmb1/δm B cells with 
nitro-phenol-coupled beads and eluted with 5 mM nitro-iodo-phenol. The eluates were subjected to a lipid-PD assay with uncoupled, 
stearate- or cholesterol-coupled sepharose beads and the bound proteins detected by WB. In the second row, the supernatant after the PD was 
analysed, showing that most, if not all, resting TCRs possess the capacity to bind to cholesterol. 
(G) Jurkat cells were stimulated as described in Figure 1E. After lysis, a PD assay with stearate- coupled beads was performed and analysed 
as in Figure 1E top panels. 
(H) An experiment as in Figure S1G using palmitate-coupled beads was performed and analysed as in Figure 1F. We conclude that the 
palmitate-TCR interaction is not influenced by the conformational state of the TCR. 
(I) Mouse CD3ε in its wild type (wt) and mutant K76T forms were lentivirally expressed in human Jurkat cells. Cells were stained with the 
anti-mouse CD3ε antibody 145-2C11. The flow cytometric analysis shows that the K76T TCR (green) has an approximately two-fold 
reduced surface expression compared to the wt TCR (black) as already reported when expressed in murine T cells (Martinez-Martin et al., 
2009). The parental Jurkat cells did not express any mouse CD3ε chains (grey). 
This figure corroborates the finding that stimulated TCRs (whether expressed in Jurkat cells or in primary human T cells) lose their capacity 
to bind to cholesterol. In contrast, the binding of the TCR to stearate and palmitate was not altered by stimulation. 
 
Supplemental Text & Figures Click here to download Supplemental Text & Figures
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Figure S2.  Analysis of the TMchim TCR, Related to Figure 2 
(A) Jurkat cells expressing the αβTCR (lane 1) or the human Vγ9Vδ2 TCR (lane 2) were cultured for 16 h with 200 µCi/ml 
photocholesterol, and the diazirin group was activated by UV light. After lysis, TCRs were immunoprecipitated (IP) using anti-TCRβ or anti-
TCRγδ antibodies and separated by reducing SDS-PAGE. The autoradiogram (top) and anti-CD3ε WB (bottom) are shown. 
(B) The amino acid sequences of the TM and cytoplasmic regions of human TCRβ1, human TCRγ2 and the TMchim TCRβ chain are 
shown. Annotation of the TM regions was done according to (Backstrom et al., 1996; Petersen et al., 2004). 
(C) The scTCR contains the scTCRβ chain that is composed of a single chain (sc) construct of the variable immunoglobulin (Ig) domains of 
a nitro-phenol (NP)-specific antibody (scFv) connected by a linker of 8 amino acids to the N terminus of wt TCRβ (Minguet et al., 2007). NP 
binding to the scTCR does not influence the conformational state of the TCR (Minguet et al., 2007). 
(D) wt scTCRβ and TMchim scTCRβ-expressing cells were stained with anti-human TCRβ (Jovi3) and PE-coupled anti-mouse IgG. Both 
scTCRβ chains (wt blue, TMchim orange) are expressed on the cell surface to equal levels. The parental 31-13 cells did not express any 
TCRβ chain (grey). 
(E) wt scTCRβ and TMchim scTCRβ were expressed in the TCRβ-deficient 31-13 Jurkat-derived cell line. These cells were lysed in 1% 
digitonin, the scTCR was affinity-purified by NP-sepharose beads and eluted using 5 mM free NIP. After separation by BN-PAGE, WB was 
done with an anti-CD3ζ antibody, showing that the TMchim TCR had the same size as the wt TCR. This suggested that the stoichiometry 
was the same in both TCRs. 
(F) Wt TCR and TMchim TCR-expressing cells were stained with the antibody Jovi1 that recognizes the constant Ig domain of TCRβ, but 
only when this domain is folded correctly (Huppa and Ploegh, 1997), and with the anti-CD3 antibody UCHT1 which only recognizes folded 
CD3ε (Arnett et al., 2004). A FITC-labelled secondary antibody recognizing Jovi1 and UCHT1 was used and the fluorescence intensity was 
measured by flow cytometry. Staining with the secondary antibody alone served to substract the background staining intensity. Triplicates 
were done and the ratio of the MFI (UCHT1) versus MFI (Jovi1) is displayed. Since this ratio was similar, we conclude that the TMchim 
TCR was folded properly concerning the two epitopes bound by these antibodies. 
(G) Binding of the wt and TMchim TCR to cholesterol- (left) or palmitate (right) -coupled beads was quantified and calculated as in Figure 
1F, showing that the capacity to bind to cholesterol, but not to palmitate, was reduced in the TMchim TCR compared to the wt TCR. 
(H) Cells were stimulated as in Figure 2B with the exception that the stimulation lasted for 7 h. Then cells were stained with an APC-coupled 
anti-CD69 antibody and analysed by flow cytometry. The percent of CD69-positive living cells is displayed. This experiment shows that the 
mutant TCR defective in cholesterol binding is partially active in non-stimulated cells. 
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Figure S3.  Cholesterol prevents spontaneous TCR signaling, Related to Figure 3 
(A) Jurkat cells were treated with cholesterol oxidase or not for 6 hours. The cells were then stained with anti-CD69 antibodies and analysed 
by flow cytometry. The normalized MFI is shown. 
(B) Human peripheral blood mononuclear cells (PBMCs) from a healthy donor were left untreated (-) or treated with cholesterol oxidase for 
1 h at 37°C. Cells were fixed, permeabilized, stained with anti-phospho-Erk and anti-CD3ε (UCHT1). The mean fluorescence intensity 
(MFI) of phospho-Erk on gated UCHT1-positive cells is shown (left panel). As a negative control, untreated T cells were stained solely with 
the secondary antibody (yellow histogram). The normalised MFI of phospho-Erk on gated UCHT1-positive cells is shown in the right panel. 
As observed in Jurkat cells (Figure 3B), cholesterol oxidation in PBMCs also led to a statistically significant increase in phospho-Erk. 
(C) Jurkat cells were treated with cholesterol oxidase for 1 h at 37°C or not. Subsequently, cells were stained with the Fixable Viability Dye 
eFluor 780 (eFluor780, eBioscience) and measured by flow cytometry. Living and dead cells, which spontaneously occur in small amounts 
in our cultures, were gated using the forward and side scatter. The intensity of the fluorescent dye in each gate displayed. This experiment 
shows that cholesterol oxidase did not affect viability of the cells. 
(D) Jurkat cells were treated with 10 mM methyl-β-cyclodextrin for 1 min at 37°C or left untreated. The SH3-PD assay to measure active 
TCRs, and anti-CD3ε IP were performed as above. This experiment shows that cholesterol extraction leads to a switch of the TCRs from 
TCRI to TCRA and to weak phosphorylation of CD3ζ. 
(E) wt scTCRβ- and TMchim scTCRβ-expressing cells were left untreated or treated with cholesterol oxidase for 1 hr. After lysis, an SH3-
PD assay was carried out. The purified proteins and the lysate were subjected to WB analysis as shown. This experiment indicates that in the 
TMchim TCRs defective in cholesterol binding the equilibrium between TCRI and TCRA is shifted towards the active state, and that 
cholesterol oxidation does not further cause that the TMchim TCRs switch to the active conformation. Likewise, phospho-Erk levels are not 
increased by cholesterol oxidation in the TMchim TCR-expressing cells.  
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Figure S4. The K76T CD3ε-containing TCR has impaired signaling activity, Related to Figure 4 
(A) Jurkat cells were illuminated with UV light or not. Subsequently, the cells were left unstimulated, or stimulated for 5 min at 37°C with 
anti-human CD3ε (OKT3) or pervanadate. After cell lysis an anti-CD3 immuno-precipitation was performed, proteins separated by SDS-
PAGE and visualised in WB using anti-phosphoY142-CD3ζ and anti-CD3ε antibodies. This experiment demonstrates that UV exposure 
prior to anti-CD3 or pervanadate treatment did neither influence the background nor the stimulus-induced phosphorylation of CD3ζ. 
(B) The background-corrected band intensities of phospho-CD3ζ, phospho-CD3ε and TCR-recruited ZAP70 were divided by the band 
intensities of CD3ζ as shown in figure 4E, lanes 3-6. Values of the wt murine TCR were normalized to 1. Phosphorylation of CD3 and 
ZAP70, as well as its recruitment to the mutant K76T TCR were statistically reduced. 
(C) Jurkat cells expressing wt and K76T murine CD3ε were left unstimulated (-), stimulated with 12µg/ml anti-mouse CD3ε (145-2C11) or 
anti-human CD3ε (OKT3). After incubation for 6 h at 37°C, cells were analysed for CD69 expression by flow cytometry. The percent of 
CD69-positive living cells is displayed. The results show that the K76T TCR has a statistically significantly reduced capacity to upregulate 
CD69 expression upon anti-mouse CD3 stimulation. As a control, the endogenous wt TCRs stimulated with anti-human CD3, were 
functional in both cells.  
(D) The cells as in (C) were stained with the anti-mouse CD3ε antibody 145-2C11 (black and green), or left unstained (light and dark blue). 
The region gated for equal expression of the TCR is indicated.  
(E) The cells as in (C) were left untreated or stimulated for 5 min with pervanadate as indicated. After fixation cells were stained with anti-
mouse CD3ε and after further permeabilisation with anti-phospho-Erk antibodies. After flow cytometric measurement, cells were gated on 
similar TCR expression (the gate is shown in (D) and the fluorescence intensity of phospho-Erk plotted (left panel). The MFI of the phospho-
Erk signals were normalized to the unstimulated wt or K76T cells (right panel). 
(F) Cells were stimulated stained and analysed as in (E) with the exception that anti-phospho-ZAP70 was used instead of anti-phospho-Erk. 
The MFI of the phospho-ZAP70 signals were normalized to the unstimulated wt or K76T cells. 
Together, these experiments show that the mutant K76T TCR, which cannot switch to the TCRA, state has an impaired signalling capacity 
whether stimulated by antibodies (as published (Martinez-Martin et al., 2009)) or pervanadate, which inhibits phosphatases but does not 
change the TCRI-TCRA equilibrium (Gil et al., 2002). 
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Figure S5.  Only TCRs in the active state are accessible for phosphorylation, Related to Figure 5 
(A) The lysates of wt scTCRβ-expressing cells were left untreated or incubated with the indicated antibodies for 90 minutes at 4ºC. TCRs 
were then purified with nitro-phenol-coupled beads and incubated with recombinant, active Lck and ATP at 30°C for 30 minutes. The 
reaction was stopped by adding non-reducing sample buffer. The purified TCRs were further treated with N-glycosidase F to cleave N-linked 
carbohydrate moieties and allow us to distinguish electrophoretically between the CD3ε and CD3δ chains. In parallel, the SH3-PD assay was 
performed and an aliquot of the total cellular lysate was loaded as a control. WB was done using anti-ζ, anti-phospho-tyrosine (4G10), anti-
δ, anti-phospho-εY1, anti-ζ and anti-ζ antibodies (top to bottom). 
(B) wt scTCRβ-expressing cells were loaded with Indo-1 and stimulated with the indicated antibodies to induce TCR-mediated Ca2+ 
responses. PBS was added to the control. The Indo-1 ratio was integrated over 8 minutes and measured by flow cytometry. The stimuli were 
added after 1 minute. Together with A) this experiment shows that the amount of TCRs in the TCRA state correlates with the amount of Ca2+ 
influx. 
(C) Membrane patches of T1.4 cells were treated with pMHC tetramers, anti-CD3ε (145-2C11) antibodies or left untreated and then 
irradiated with UV-light to crosslink the pMHC tetramers to the TCRs. After addition of ATP and recombinant-active Lck, phosphorylation 
reactions were carried out for 15 min at 30°C. Proteins were then analysed by WB using anti-phospho-εY1, anti-phospho-tyrosines (4G10), 
anti-ζ and anti-β2 microglobulin antibodies (top to bottom). In parallel, the SH3-PD assay was performed (lower panel). 
This figure shows that stabilisation of the TCRA state by pMHC tetramer or antibody stimulation renders the ITAMs of CD3ε, CD3δ and 
CD3ζ available for phosphorylation by active Lck. 
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Figure S6.  A lipid-regulated allosteric model for TCR triggering, Related to Figure 6 
A) Wt and TMchim TCR-expressing cells were left unstimulated (-) or stimulated with 5 µg/ml anti-CD3ε (OKT3) for 5 min at 37°C. After 
lysis the lysate was split in two halves, an SH3-PD (TCRAs) and an anti-CD3ε immuno-precipitation (total TCRs) were performed. Purified 
proteins were analysed by WB using anti-CD3ζ antibodies. The percentage of active TCRs was calculated from the CD3ζ band intensities 
(n=3). 
B) Calculation of the parameters and their values according to the allostery model of TCR phosphorylation in Figure 6A. In the third column 
the 95% confidence intervals are given in brackets. 
C) Lymph node cells as in Figure 6C were stained on ice for 30 min with increasing concentrations of PE-labeled wt OVA-H2-Kb tetramers 
(that can bind to CD8) and then with an anti-Vα2 antibody. Flow cytometry measurement to quantify the amount of bound tetramers was 
done as in Figure 6C (n=3), including gating on cells with similar TCR expression level and normalization to the TCR level. * p < 0.05, *** 
p < 0.001 by unpaired t-test. 
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Figure S7.  Allosteric model for TCR triggering with ligand-induced TCR clustering, Related to Figure 6 
(A) This model is analogue to the one from Figure 6, except that TCRs are expressed as monomers and only cluster upon multivalent pMHC 
binding (crosslinking). In this model pMHC dimers can only cluster two TCRA, but not two TCRI or TCRA with TCRI. The partition function 
of this model is given by Z = 1 + α + αβ[T] + L(1+ α)(1+γ) where [T] denotes the concentration of pMHC-unbound TCRA and all other 
parameters are as defined in Supplemental Experimental Procedures. 
(B) All calculated parameters of the “ligand-induced TCR clustering” model from (A) were the same as in the related model from Figure 6A, 
except Ka and Kb, which are shown here. 
(C) The experimental D227K-pMHC tetramer binding data from Figure 6C were used to fit to the “ligand-induced TCR clustering” model 
from panel A. The best fit of the model to the data is shown by solid lines, indicating that this model is also in line with the data. Thus, the 
clustering mechanism of the TCR does not affect the interpretation of the data. 
(D, E) Analyses of the “ligand-induced TCR clustering” model were done as in Figures 6D and 6E. The results are very similar, indicating 
that the role of cholesterol in controlling the conformational switch in the TCR and in regulating pMHC tetramer binding is independent of 
whether TCR are nanoclustered or clustered by the pMHC tetramer.	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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
 
Cells, Cloning and Transfection 
The mouse T-cell line T1.4, the human T-cell line Jurkat, variants of Jurkat, the human B-cell line 
J558Lmb1/δm and the mouse T-cell lines M.mζ-SBP and M.hTfR-SBP (Molnar et al., 2012) were grown in 
complete RPMI-1640 medium supplemented with 5% bovine serum and antibiotics at 37°C. Human peripheral 
blood mononuclear cells were isolated from healthy donors according to the local ethics committee requirements 
for human experimentation and purified by Ficoll gradient centrifugation. Jurkat cells were transduced with 
lentiviruses harbouring the plasmids pHRSIN-mCD3ε and pHRSIN-mCD3ε(K76T) (Martinez-Martin et al., 
2009) to yield J.mCD3ε and J.mCD3ε(K76T). pHRSIN-mCD3ε(C80G) was also used, but in this case the Jurkat 
transductants did not express large amounts of the mutant TCR on their surface (data not shown). 
To generate the wt scTCR and the TMchim scTCR, the following strategy was used. The coding sequence for 
the scTCRβ chain was amplified by PCR from pSRscTCRβ (Minguet et al., 2007) and cloned into the 
HpaI/EcoRI site of pCDNA3.1 to yield the retroviral expression vector pCDNA3-scTCRβ. The expression 
vector pCDNA3-scTCRβ-γTM was generated by linking the PCR product corresponding to the leader peptide 
and extracellular regions of the scTCRβ molecule to the PCR product corresponding to the TM and cytoplasmic 
domains of the human TCRγ2 molecule by nested PCR and cloning the resulting PCR product into the 
HpaI/EcoRI site of pCDNA3.1 The Jurkat-derived TCRβ-negative cell line 31-13 was transfected with the 
plasmids pCDNA3-scTCRβ or pCDNA3-scTCRβ-γTM to yield 31-13.scTCRβ (wt scTCRβ) and 31-
13.scTCRβ-γTM (TMchim scTCRβ) cell lines.  
 
Reagents 
The following antibodies were used:  anti-CD3ε and anti-CD3δ (M20ε and M20δ, Santa Cruz Biotechnology), 
 anti-hCD3-Alexa647 (UCHT1 Biolegend), anti-phospho-tyrosine (4G10, Upstate Biotechnology), anti-ζ 448 
(San Jose et al., 1998), anti-phospho-Erk (Cell Signalling), anti-Erk2 (BD Transduction), anti-hCD3 (UCHT1, 
Dr. Beverly, UK), anti-hCD3ε (OKT3, Ortho), anti-mCD3ε (145-2C11, Biolegend), anti-mCD3ε APC (145-
2C11, eBioscience), anti-CD69 FITC (Biolegend), anti-Bub3 (Abcam), anti-TfR (7F8, Abcam), anti-IgD-HRPO 
(Nordic), anti-TCR Cβ1 (Jovi1), anti-Vα2 PE (B20.1, BD Pharmingen), anti-phospho-εY1 (Dopfer et al., 2010), 
pan anti-phospho-ζ (also called anti-phospho-εY2) (Dopfer et al., 2010),  anti-phospho-ζ (pY142, Sigma) anti-
β2microglobulin (Santa Cruz Biotechnology), anti-phospho ZAP70 (phospho-319, BD Biosciences or Cell 
Signalling), anti-ZAP70 (Santa Cruz Biotechnology), anti-actin (Sigma), anti-rabbit DyLight633 (Thermo 
Scientific), anti-mouse IgG PE (Southern Biotech), anti-mouse IgG APC (Southern Biotech), anti-GST (Bethyl) 
and secondary antibodies for Western Blot (Southern Biotech, LI-COR). Nitro-iodo-phenol and nitro-phenol-
coupled beads were purchased from Biosearch Technologies. N-glycosidase F was from Roche Diagnostics, 
cholesterol oxidase, MβCD and all other chemicals were from Sigma. Recombinant active GST-Lck was from 
Enzo Life Sciences. Since GST is at the N-terminus and the fusion protein expressed in E. coli, GST-Lck neither 
contains N-myristoylations (Duronio et al., 1990; Knoll and Gordon, 1993) nor S-palmitoylations (Greentree and 
Linder, 2004), and thus is not post-translationally modified by any fally acid. 
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Ca2+ influx 
Cells resuspended in RPMI-1640 medium with 1% serum were incubated with 5 µg/ml Indo-1 and 0.5 µg/ml of 
pluronic F-127 (both Molecular Probes) at 37°C for 45 minutes. After washing, cells were resuspended in 
RPMI-1640 medium with 1% serum and kept on ice. Ca2+ influx was induced by addition of the indicated stimuli 
1 min after starting to record the ratio of Ca2+-bound Indo-1 versus unbound Indo-1 with a LSRII fluorescence 
spectrometer (Becton Dickinson). Data were analysed with FlowJo 8.2 software. 
 
Cell treatments and lysis 
5 - 30 million cells were harvested per sample, resuspended in 0.5 - 1 ml medium without serum, and incubated 
for 1 h at 37°C. TCR stimulation was performed at 37°C with 5 µg/ml antibody (anti-mCD3ε clone 145-2C11, 
anti-hCD3ε clone UCHT1 or clone OKT3 as indicated and anti-TCRβ clone Jovi1) or the given concentrations 
of pervanadate (50 µM: 100 µl Na3VO4 50 mM, 0.5 µl H2O2) for 5 minutes, if not otherwise indicated. To 
oxidize cell surface cholesterol, 30 million cells were pelleted per sample, resuspended in 1 ml RPMI-1640 
medium supplemented with 5% lipid-depleted, charcoal-stripped fetal calf serum (Biowest), and incubated for 1 
hour at 37°C. Subsequently, cells were treated with 0.5 U/ml cholesterol oxidase (Sigma) at 37ºC for the times 
indicated. To extract cholesterol, cells were treated with 10 mM methyl-β-cyclodextrin at 37°C for the times 
indicated. Dead cell were stained with a 1:1000 dilution of the Fixable Viability Dye eFluor® 780 (eBiosciene) 
30 min  before the flow cytometric measurement.  
Cell lysis was done in 1 ml lysis buffer containing 20 mM TrisHCl (pH8), 137 mM NaCl, 2 mM EDTA, 10% 
glycerol, protease inhibitor cocktail (Sigma), 1 mM PMSF, 5 mM iodoacetamide, 0.5 mM sodium 
orthovanadate, 1 mM NaF and 0.05% - 0.5% Brij96 for 15 minutes on ice, followed by a 15 minutes 
centrifugation in an Eppendorf centrifuge to pellet the nuclei and insoluble materials. 
 
Reconstitution of CD3 phosphorylation in membranes 
Membrane fractions were prepared by disrupting 3 x 107 T1.4, Jurkat or 31-13.scTCRβ cells in hypoosmotic 
buffer (10 mM HEPES [pH 7.4], 42 mM KCl, 5 mM MgCl2, and protease inhibitors) with a Dounce 
homogenizer and pelleting the membranes in an ultracentrifuge at 150,000 x g. The membranes from T1.4 cells 
were resuspended in PBS supplemented with 50 mM pMHC tetramer (4P peptide: (SYIPSAEK(ABA)I, H2Kd, 
kindly provided by Immanuel Lüscher (Luescher et al., 1994)) or 20 µg/ml anti-CD3 (145-2C11). After addition 
of active-recombinant GST-Lck and ATP, CD3 phosphorylation was done as above. 
 
Allostery model of TCR opening 
The model considers a preformed TCR dimer bound by dimeric pMHC ligands. Following the Monod-Wyman-
Changeux model (Monod et al., 1965), we assume that the two TCRs can undergo a concerted transition between 
the inactive (TCRITCRI) and the active (TCRATCRA) conformations; the conformational equilibrium constant in 
the absence of pMHC or cholesterol is denoted by L = [TCRITCRI]/[TCRATCRA], for simplicity expressed as L 
= [TCRI]/[TCRA]. Both TCRI and TCRA bind pMHC monovalently with the same affinity Ka (in addition to the 
states shown in Figure 6A, a TCR dimer can also bind to pMHC monovalently). In the active conformation, a 
single monovalently bound ligand can bind the second TCR with affinity Kb. In the inactive state, cholesterol 
binds to the TCR with equilibrium constant Kc. Defining the dimensionless parameters α = Ka x [pMHC], β = Kb, 
	  	   10	  
and γ = Kc x [cholesterol], where [pMHC] and [cholesterol] denote the concentrations of free pMHC dimers and 
membrane cholesterol, respectively, the partition function of this system reads: Z = (1+α)2 + αβ + L[(1+α)2 + 
(1+γ)2]. From Z, the fractions of the various states shown in Figure 6 were calculated. For all experiments with 
unstimulated cells, α = 0. To simulate the anti-CD3 activation experiments (Figure 6B), we used the wt TCR 
data to fit the effective free parameters α and β / (1+ α)2, thus fixing the degree of crosslinking by anti-CD3, and 
used these parameters to make the prediction for TMchim TCR. For fitting the pMHC binding data in Figure 6C, 
we used the L and Kc determined above and estimated Ka and Kb by a maximum likelihood approach; for the 
C80G CD3ε mutant, L →∞. 95% confidence intervals were calculated by parametric bootstrap. For Figure 6D, 
we took Ka = 1 µM–1 to compute α for the given pMHC concentrations (Huang et al., 2010).  
Additionally we developed a model without pre-clustering of the TCR (Figure S7). Here, the partition function is 
given by Z = 1 + α + αβ[T] + L(1+ α)(1+γ) where [T] denotes the concentration of open TCRs that did not bind 
to ligand. The remaining notation is as given above. 
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